Navigation Links
BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Date:1/30/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Jan. 30 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting MS. The lead clinical development program for dirucotide is for secondary progressive MS where it is being evaluated in two ongoing phase III trials in the United States, Canada and Europe, with results from the Canadian and European MAESTRO-01 trial expected in the second half of 2009.

The results of the MINDSET-01 study showed that dirucotide did not meet its primary endpoint, annualized relapse rate or associated secondary MRI endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) score. The EDSS is a method of quantifying disability in MS, while the MSFC evaluates additional functional parameters. Measuring changes in EDSS and MSFC are primary and secondary outcomes in the ongoing phase III secondary progressive MS trials.

The data also showed that dirucotide was generally well tolerated. The most common side effects reported were redness and burning sensation at the injection site. No patients withdrew due to adverse events.

BioMS and its partner Eli Lilly & Company (Lilly) will continue to analyze the results of this exploratory phase II trial. Under the terms of the licensing agreement with Lilly, no milestone payment was associated with this trial.

"We are encouraged that dirucotide has demonstrated an effect on certain clinical measures of disease progression, this time in the earlier form of the disease," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was developed as a potential treatment f
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical recognized at Scrip Awards 2008
2. BioMS Medical Announces Third Quarter 2008 Results
3. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
4. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
5. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
6. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
7. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
8. BioMS Medical to present at UBS Global Life Sciences Conference
9. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
10. BioMS Medical announces its intention to renew a normal course issuer bid
11. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... PAREXEL International Corporation (Nasdaq: ... organization , announced today that the Company ... all of the business assets of privately-owned Quantum ... specialized pharmacovigilance services, based in Chandigarh, India.  ... monitoring, and prevention of adverse effects with ...
(Date:3/26/2015)... "In America," the popular news television program that ... hosted by legendary film actor James Earl Jones, has announced ... upcoming segment. , Botany is commonly described as the ... quite a bit more complicated than that. Scientists and other ... organisms, from the smallest bacteria known to man to the ...
(Date:3/26/2015)... March 26, 2015 WriteResult, a premier ... researchers from Yale University’s School of Public Health and ... participants during a 4 month-long project. The goal of ... low income families with free access to fresh produce ... diet-related health concerns like high blood pressure, diabetes and ...
(Date:3/25/2015)... Balaton, MN (PRWEB) March 26, 2015 ... an upcoming episode of American Farmer, airing for the ... RFD-TV. The segment of American Farmer will explore the ... Agnition provides crop producers with a patented Microbial Catalyst™ ... farms and greater yields. The segment will air again ...
Breaking Biology Technology:PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3Agnition to be Featured In Upcoming Episode of American Farmer on RFD-TV 2
... a global chemistry-driven contract research organization, announced today that ... one of the leading CRO companies conducting high quality ... Prudentas will continue to operate separately under the business ... to the acquisition ChemDiv had worked with Prudentas, who ...
... Science, Scale and Talent Required to Meet Growing Demand , ... ... enable farmers to produce enough grain to meet the growing demand ... regulators and policymakers from around the globe take a more holistic ...
... Accreditation StandardsWASHINGTON, April 16 URAC ... announced today that Director of Pharmacy Programs Janice Anderson, ... 21st Annual Academy of Managed Care Pharmacy (AMCP) ... health care professionals dedicated solely to the issues of ...
Cached Biology Technology:ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center 2ChemDiv Group Acquires Prudentas Through ChemRar High Tech Center 3DuPont Leader: Agriculture is Up to Global Productivity Challenge 2DuPont Leader: Agriculture is Up to Global Productivity Challenge 3DuPont Leader: Agriculture is Up to Global Productivity Challenge 4URAC Director of Pharmacy Programs to Speak at Academy of Managed Care Pharmacy Annual Meeting 2URAC Director of Pharmacy Programs to Speak at Academy of Managed Care Pharmacy Annual Meeting 3
(Date:3/20/2015)... and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has announced the ... Report" report to their offering. This report ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... . Annual estimates and forecasts are provided ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... March 12, 2015 The mascots of the ... Hospital, part of Wake Forest Baptist Medical Center. They ... the 2015 ACC Men,s Basketball Tournament. Young patients enjoyed ... and getting their autographs. Brenner Children,s Hospital ... is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... to display the earliest signs of Parkinson,s disease using the ... the disease. The mouse model, which expresses the same ... of constipation and other gastrointestinal problems that are a common ... result, researchers say, these animals could serve as a means ...
... Bethesda, MarylandThe American Association of Anatomist,s (AAA) presented its ... Meeting in Anaheim. This year,s honors went to: ... Dept. of Cell and Developmental Biology at SUNY Upstate ... the 2010 Henry Gray/ Lippincott Williams & Wilkins Scientific ...
... in Spanish . ANN ARBOR, Mich. ... treat breast cancer by targeting cancer stem cells -- the ... according to a new study from researchers at the University ... a component of broccoli and broccoli sprouts, in both mice ...
Cached Biology News:UCSF transgenic mouse mimics Parkinson's earliest symptoms 2UCSF transgenic mouse mimics Parkinson's earliest symptoms 3Broccoli component limits breast cancer stem cells, U-M study finds 2
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
... The Helios gene gun system, 220-240 V, ... biomaterials into cells. This handheld device employs ... RNA-, and other biomaterial-coated gold microcarriers from ... cartridge directly into target cells. This system ...
Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
... DNA Technologies also offers a DNA sequencing ... templates including plasmids, PCR products, BACs, etc. ... templates such as purified plasmids or purified ... handling robotics optimized for automated reaction setup ...
Biology Products: